Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LXH 254 + Nazartinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LXH 254||LXH254|LXH-254|Naporafenib||BRAF Inhibitor 25 CRAF Inhibitor 12||LXH 254 is a RAF inhibitor that selectively inhibits monomeric and dimerized BRAF and CRAF, which may lead to anti-tumor activity in RAF-mutant tumors and better tolerability (AACR Annual Meeting 2019, Abstract LB-114, PMID: 31059256).|
|Nazartinib||EGF816|EGF-816||EGFR Inhibitor 3rd gen 26||Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829, PMID: 31954624).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03333343||Phase I||LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib||Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC||Active, not recruiting||ITA | DEU | CAN||3|